IgA nephropathy: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BCMA 7
• CD19 8
• SGLT2 1
• CD20 0
• CD38 0
• IL-6 0
• JAK 0
• NLRP3 0
• TLR4 0
• mTOR 0
• STING 0
• IL-17 0
• AKT 0
• AMPK 0
• EGFR 0
• FAK 0
• GPX4 0
• HER2 0
• IL-1 0
• MET 0
• MYC 0
• NRF2 0
• PD-1 0
• PI3K 0
• STAT3 0
• TP53 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 369 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients

  NCT07022574· University of California, Los Angeles· Updated 27 Jul 2026

  “Unable to recruit”Registry text, quoted unchanged. Source

• Terminated

  Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

  NCT03608033· Omeros Corporation· Updated 9 Dec 2025

  “IA did not meet the prespecified primary endpoint.”Registry text, quoted unchanged. Source

• Withdrawn

  An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

  NCT06926985· Jieyang People's Hospital· Updated 4 Jul 2025

  “Due to limitation of production capacity”Registry text, quoted unchanged. Source

• Terminated

  Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

  NCT05847920· Guangdong Hengrui Pharmaceutical Co., Ltd· Updated 5 Mar 2025

  “Based on the adjustment of the R \& D strategy, the sponsor decides to terminate the research.”Registry text, quoted unchanged. Source

• Terminated

  A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

  NCT04905212· RemeGen Co., Ltd.· Updated 6 Dec 2023

  “Decision that continuing with the study would not generate useful data”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

  NCT07498335· Novartis Pharmaceuticals· Source

• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Takeda· Source

• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Novartis Pharmaceuticals· Source

• Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

  NCT05517980· Kira Pharmacenticals (US), LLC.· Source

• A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials

  2024-519638-22-00· Novartis Pharma AG· Source

• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Hoffmann-La Roche· Source

• Phase 2b Open-Label Repeat Kidney Biopsy Study

  NCT06740526· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT07889362· Biogen· Source

• A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

  NCT07146906· Novartis Pharmaceuticals· Source

• Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)

  NCT07770815· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 14
• Gene Expression Profiling 14
• Proteomics 8
• Metabolomics 5
• Flow Cytometry 2
• Immunohistochemistry 4
• Magnetic Resonance Imaging 1
• Machine Learning 9
• Deep Learning 3
• Cohort Studies 13
• Genome-Wide Association Study 20

• Deep Learning-Enabled Interpretative SERS Analysis of Key Urinary Metabolites in Nephropathy Using Interfacial Charge-Engineered Silver Nanoparticles.

  Anal Chem, Oct 2026

• Clinical application of deep learning-based measurement of glomerular morphometry in IgAN.

  Front Immunol, Aug 2026

• Risk prediction in IgA nephropathy: from conventional models to machine learning, deep learning, and precision nephrology.

  Ren Fail, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.